158 related articles for article (PubMed ID: 21894005)
1. Endothelin antagonists in clinical trials: lessons learned.
Barton M; Kohan DE
Contrib Nephrol; 2011; 172():255-260. PubMed ID: 21894005
[TBL] [Abstract][Full Text] [Related]
2. Clinical trials with endothelin receptor antagonists: what went wrong and where can we improve?
Kohan DE; Cleland JG; Rubin LJ; Theodorescu D; Barton M
Life Sci; 2012 Oct; 91(13-14):528-39. PubMed ID: 22967485
[TBL] [Abstract][Full Text] [Related]
3. Endothelin Receptor Antagonists in Kidney Disease.
Martínez-Díaz I; Martos N; Llorens-Cebrià C; Álvarez FJ; Bedard PW; Vergara A; Jacobs-Cachá C; Soler MJ
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834836
[TBL] [Abstract][Full Text] [Related]
4. Update on Endothelin Receptor Antagonists in Hypertension.
Burnier M
Curr Hypertens Rep; 2018 May; 20(6):51. PubMed ID: 29779164
[TBL] [Abstract][Full Text] [Related]
5. Endothelin receptor antagonists in clinical research--lessons learned from preclinical and clinical kidney studies.
Reichetzeder C; Tsuprykov O; Hocher B
Life Sci; 2014 Nov; 118(2):141-8. PubMed ID: 24607774
[TBL] [Abstract][Full Text] [Related]
6. Endothelin Receptor Antagonists: New Hope for Renal Protection?
Tobe S; Kohan DE; Singarayer R
Curr Hypertens Rep; 2015 Jul; 17(7):57. PubMed ID: 26068660
[TBL] [Abstract][Full Text] [Related]
7. Endothelin Receptor Antagonists: Status Quo and Future Perspectives for Targeted Therapy.
Enevoldsen FC; Sahana J; Wehland M; Grimm D; Infanger M; Krüger M
J Clin Med; 2020 Mar; 9(3):. PubMed ID: 32197449
[TBL] [Abstract][Full Text] [Related]
8. Systematic Review of Randomized Controlled Trials of Endothelin Receptor Antagonists for Pulmonary Arterial Hypertension.
Kuntz M; Leiva-Juarez MM; Luthra S
Lung; 2016 Oct; 194(5):723-32. PubMed ID: 27506903
[TBL] [Abstract][Full Text] [Related]
9. Endothelin receptor antagonism in portal hypertension.
Pitts KR
Expert Opin Investig Drugs; 2009 Feb; 18(2):135-42. PubMed ID: 19236261
[TBL] [Abstract][Full Text] [Related]
10. Association of oral endothelin receptor antagonists with risks of cardiovascular events and mortality: meta-analysis of randomized controlled trials.
Pan Y; Hu C; Chen PH; Gu YH; Qiao QY; Pan LH; Zhou DC; Gu HF; Fu SK; Jin HM
Eur J Clin Pharmacol; 2017 Mar; 73(3):267-278. PubMed ID: 27957707
[TBL] [Abstract][Full Text] [Related]
11. Atrasentan for the treatment of diabetic nephropathy.
Egido J; Rojas-Rivera J; Mas S; Ruiz-Ortega M; Sanz AB; Gonzalez Parra E; Gomez-Guerrero C
Expert Opin Investig Drugs; 2017 Jun; 26(6):741-750. PubMed ID: 28468519
[TBL] [Abstract][Full Text] [Related]
12. Endothelin receptor antagonists for pulmonary arterial hypertension.
Liu C; Cheng J
Cochrane Database Syst Rev; 2005 Jan; (1):CD004434. PubMed ID: 15674947
[TBL] [Abstract][Full Text] [Related]
13. Endothelin in health and disease: endothelin receptor antagonists in the management of pulmonary artery hypertension.
Kim NH; Rubin LJ
J Cardiovasc Pharmacol Ther; 2002 Jan; 7(1):9-19. PubMed ID: 12000973
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic potential of endothelin receptor antagonists for chronic proteinuric renal disease in humans.
Barton M
Biochim Biophys Acta; 2010 Dec; 1802(12):1203-13. PubMed ID: 20359530
[TBL] [Abstract][Full Text] [Related]
15. The Role of Endothelin and Endothelin Antagonists in Chronic Kidney Disease.
Raina R; Chauvin A; Chakraborty R; Nair N; Shah H; Krishnappa V; Kusumi K
Kidney Dis (Basel); 2020 Jan; 6(1):22-34. PubMed ID: 32021871
[TBL] [Abstract][Full Text] [Related]
16. Drug Insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases.
Humbert M; Simonneau G
Nat Clin Pract Rheumatol; 2005 Dec; 1(2):93-101. PubMed ID: 16932638
[TBL] [Abstract][Full Text] [Related]
17. Endothelin receptor antagonists for the treatment of pulmonary artery hypertension.
Rubin LJ
Life Sci; 2012 Oct; 91(13-14):517-21. PubMed ID: 22884806
[TBL] [Abstract][Full Text] [Related]
18. Profile of past and current clinical trials involving endothelin receptor antagonists: the novel "-sentan" class of drug.
Battistini B; Berthiaume N; Kelland NF; Webb DJ; Kohan DE
Exp Biol Med (Maywood); 2006 Jun; 231(6):653-95. PubMed ID: 16740981
[TBL] [Abstract][Full Text] [Related]
19. Endothelin antagonism and reversal of proteinuric renal disease in humans.
Barton M
Contrib Nephrol; 2011; 172():210-222. PubMed ID: 21894001
[TBL] [Abstract][Full Text] [Related]
20. Targets for endothelin in the diseased kidney: clues for therapeutic intervention.
Rohmeiss P; Birck R; Braun C; Kirchengast M; van der Woude FJ
Exp Nephrol; 1999; 7(1):1-10. PubMed ID: 9892807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
